生物活性 | |||
---|---|---|---|
描述 | DBPR108 is a highly potent, selective, and orally bioavailable dipeptide-derived inhibitor of DPP4, with an IC50 of 15 nM. It does not exhibit inhibition on DDP8 and DPP9. The IC50 value remains at 15 nM [1]. DBPR108, a DPP4 inhibitor with an IC50 of 15 nM, exhibits over 3000-fold selectivity against DPP8, DPP9, FAP, and DPP-II. Additionally, the in vivo effects of DBPR108, such as inhibiting plasma DPP-IV activity and suppressing blood glucose elevation, have been demonstrated. As a potential treatment for type 2 diabetes mellitus, DBPR108 is a potent, selective, long-acting, and safe DPP-IV inhibitor. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.08mL 0.62mL 0.31mL |
15.41mL 3.08mL 1.54mL |
30.83mL 6.17mL 3.08mL |
参考文献 |
---|